Trastuzumab emtansine in the treatment of HER-2-positive metastatic breast cancer patients

By Bighin Claudia   Pronzato Paolo   Del Mastro Lucia  

Future Oncology, Vol. 9, Iss. 7, 2013-07 ,pp. : 955-957

Future Medicine

Access to resources Recommend Favorite

Efficacy and safety of trastuzumab plus capecitabine in heavily pretreated patients with HER2-positive metastatic breast cancer

By Osako Tomo   Ito Yoshinori   Takahashi Shunji   Tokudome Nahomi   Iwase Takuji   Hatake Kiyohiko  

Cancer Chemotherapy and Pharmacology, Vol. 62, Iss. 1, 2008-06 ,pp. : 159-164

Springer Publishing Company

Access to resources Recommend Favorite

Phospho-PRAS40Thr246 predicts trastuzumab response in patients with HER2-positive metastatic breast cancer

By  

Oncology Letters, Vol. 9, Iss. 2, 2015-01 ,pp. : 785-789

Spandidos Publications

Access to resources Recommend Favorite

Serum epidermal growth factor is associated with prognosis and hormone receptor status in patients with HER2-positive metastatic breast cancer treated with first-line trastuzumab plus taxane chemotherapy

By Kim Ji-Won   Kim Jee   Im Seock-Ah   Lee Kyung-Hun   Kim Jin-Soo   Kim Tae-Yong   Han Sae-Won   Jeon Yoon   Oh Do-Youn   Kim Tae-You   Park In  

Cancer Chemotherapy and Pharmacology, Vol. 72, Iss. 5, 2013-11 ,pp. : 1023-1029

Springer Publishing Company

Access to resources Recommend Favorite

Continued Use of Trastuzumab (Herceptin) after Progression on Prior Trastuzumab Therapy in HER-2-Positive Metastatic Breast Cancer

By Pusztai Lajos   Esteva Francisco  

Cancer Investigation, Vol. 24, Iss. 2, 2006-05 ,pp. : 187-191

Informa Healthcare

Access to resources Recommend Favorite